sofosbuvir and daclatasvir for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Sadeghi IRCT20200128046294N2		RCT	sofosbuvir and daclatasvir	standard of care	COVID 19 hospitalized	some concern	35/35	suggested	suggested 2.6-fold increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Yakoot DRKS00022203		RCT	sofosbuvir and daclatasvir	standard of care	COVID 19 hospitalized	some concern	44/45	suggested	suggested 60 % increase in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis